09 July 2021
EMA/CHMP/390656/2021
EMEA/H/C/003886

Public statement

Portrazza

Expiry of the marketing authorisation in the European Union

The marketing authorisation for Portrazza (necitumumab) expired on 18 February 2021 following the decision of the marketing authorisation holder, Eli Lilly Nederland B.V., not to apply for a renewal of the marketing authorisation.

Eli Lilly Nederland B.V. confirmed that it did not apply for renewal of the authorisation due to the lack of demand for this product.

Portrazza was granted marketing authorisation in the European Union (EU) on 15 February 2016 for the treatment of squamous non-small cell lung cancer. The marketing authorisation was valid for a 5-year period.

The marketing authorisation holder has committed to ensure that patients who benefit from Portrazza for the treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer can continue to receive treatment as appropriate.

The European Public Assessment Report (EPAR) for Portrazza will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union